Item 7.01. Other Events.

As previously disclosed in the Current Report on Form 8-K filed on January 7, 2021 by PerkinElmer, Inc. (the "Company"), on January 7, 2021, the Company, PerkinElmer (UK) Holdings Limited and Oxford Immunotec Global PLC ("Oxford") entered into an Implementation Agreement (the "Implementation Agreement") under which the Company will acquire Oxford (the "Acquisition") on the terms and conditions therein.

On January 11, 2020, the Company presented at the 2021 J.P. Morgan Healthcare Conference. The Company used the materials attached as Exhibit 99.1 hereto in its presentation, and the relevant portion of the transcript of the oral presentation is attached as Exhibit 99.2

In accordance with General Instruction B-2 of Form 8-K, the information set forth in or incorporated by reference into this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

© Edgar Online, source Glimpses